Alana B. McNulty - 07 Sep 2021 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Director
Signature
/s/ Maria Dobek, Attorney-in-Fact
Issuer symbol
JANX
Transactions as of
07 Sep 2021
Net transactions value
$0
Form type
4
Filing time
09 Sep 2021, 17:36:50 UTC
Previous filing
27 Aug 2021
Next filing
24 Jan 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JANX Stock Option (right to buy) Award $0 +30,000 $0.000000 30,000 07 Sep 2021 Common Stock 30,000 $29.58 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option vest in equal monthly installments over a three year period following September 7, 2021 (the "Grant Date") such that the option is fully vested on the third anniversary of the Grant Date.